分子靶向药物

分子靶向药物联合应用及与细胞因子或传统化疗药物的联合应用正在研究中。

The study evaluating combinations of different molecular targeted agents and molecular targeted agents combined with cytokine or chemotherapy agents are ongoing .

目的：探讨胃肠间质瘤（GIST）的CT表现及分子靶向药物甲磺酸伊马替尼（STI571）对胃肠间质瘤疗效的CT评价。

Objective : To explore CT in gastrointestinal stromal tumor ( GIST ) and evaluation the GIST treated with molecular targeted drug Imatinib mesylate ( STI 571 ) by CT .

TACE联合分子靶向药物治疗原发性肝癌的研究进展

Combination of TACE with molecularly targeted agent in management of advanced HCC

根据目前的研究发现，II期临床试验计划将金硫代苹果酸盐与其他参与癌症生长的分子靶向药物联用。

Based on findings to date , a phase II clinical trial is being planned to combine aurothiomalate with agents targeted at other molecules involved in cancer growth .

分子靶向药物bevacizumab是针对血管内皮生长因子（VEGF）的重组人源化单克隆抗体，在多种恶性肿瘤的治疗中显示了临床效果。

The targeted drug bevacizumab is an anti-VEGF monoclonal antibody , it has clinical effect on many malignant tumors .

本文将对5-FU、新一代化疗药物以及分子靶向药物在转移性结肠癌治疗的演进及新进展作一综述。

In this review , we discuss the current advances in combined management of metastatic colorectal cancer of 5-Fu , chemotherapy , Molecular targeted therapy .

赫赛汀（Herceptin）是以乳腺癌HER-2基因作为治疗靶点的第一个分子靶向药物。

Herceptin is the first targeted molecular drug used breast cancer HER-2 genes as therapeutic targets , which is widely used in clinical .

Herceptin是美国FDA批准的第一种分子靶向药物，为乳腺癌尤其是HER2过表达乳腺癌的临床治疗带来了新的突破。

As the first molecular drug , which was approved by FDA , Herceptin bring a new break-through for breast cancer clinical treatment , especially for HER2 / neu positive breast cancer patients .

以表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）为基础的分子靶向药物治疗在肺癌的治疗中发挥着重要作用，成为国内外研究的热点。

The epidermal growth factor receptor kinase inhibitors ( EGFR-TKI ) play an important role in molecular target therapy of lung cancer .

分子靶向药物伊马替尼能够与Bcr-Abl激酶结合而成功治疗慢性粒细胞性白血病，然而该激酶的点突变常导致伊马替尼耐药，使治疗失败。

Molecularly targeted agent imatinib can successfully control chronic myelogenous leukemia by combining to Bcr-Abl kinase . But the mutations of Bcr-Abl kinase often result in resistance to imatinib and cause failure of treatment .

背景与目的：Herceptin是目前治疗Her2/neu高表达晚期转移性乳腺癌的常用分子靶向药物。

Background and Purpose : Herceptin could be a potential candidate for targeted therapy in Her2 / neu overexpression metastatic breast cancer , but its efficacy has proven to be limited when used as a single agent .

肿瘤的完整切除仍是首选治疗方法，分子靶向药物是治疗SIST有前途的新选择。

Surgery remains the treatment of choice in resectable disease . Radical resection of the tumor is important in treatment of SIST . Molecular targeted drugs are a promising new option .

本文介绍目前正在进行临床试验的几类分子靶向药物。

This article introduces several molecule-targeting agents that are currently under clinical trials now .

替莫唑胺及其联合分子靶向药物抗人脑胶质瘤细胞体外试验性研究

The Study of Anti-human Glioma Cells by Temozolomide Combined with Targeted Drugs in Vitro

近年研究发现，化疗药与分子靶向药物联用可以提高化疗效果。

Recent researches demonstrated combinations of targeted agents and chemotherapeutic agents could improve effect .

临床药师对1例服用分子靶向药物舒尼替尼的肿瘤患者的药学监护

Pharmaceutical Care of Clinical Pharmacist for a Cancer Patient Taking Molecular Targeted Drug : Sunitinib

针对肿瘤发展特异性生物环节的分子靶向药物治疗，为肺癌治疗开辟新途径。

Drug targeting the specific molecules of tumor development opened a new way for the treatment of lung cancer .

随着分子靶向药物的研发和临床应用，肿瘤的分子靶向治疗已成为肿瘤治疗领域研究的热点。

With the development and clinical application of molecule-targeted drugs , the molecule-targeted treatment of tumors has been widely accepted .

此外，本研究结果对于将其它现代中药制剂与分子靶向药物联合应用以提高疗效，具有重要的启迪意义。

In addition , the findings has a significant enlightening meaning on other modern Chinese medicine preparation and molecular targeting drug combination .

分子靶向药物通过阻断肿瘤细胞或相关细胞的信号转导，来控制细胞基因表达，从而抑制或杀伤肿瘤细胞。

Molecular targeted drugs block signal transduction of tumor cells or related cells to control gene expression , then to inhibit or kill tumor cells .

除了手术、放疗及传统化疗药物之外，更多研究开始关注于分子靶向药物的开发，但由于这些药物疗效的不稳定性，般仅作为肺癌治疗的二线药物。

Besides the traditional treatment , such as operation , radiotherapy and chemotherapeutics , molecular targeting therapy of lung cancer has been developed rapidly in recent years , but it is still the second-line treatment to lung cancer .

近两年来研究发现，如同小分子靶向药物治疗存在优势人群一样，化疗药物也有优势人群，如何筛选优势人群，使接受化疗的患者获益最大，避免过度治疗，是我们目前面临的主要问题。

Recently , researches have found chemotherapy medicine also had advantageous group , just as targeted medicine . Now main question we are faced with is " how to screen the advantage group , so that the greatest benefit in patients receiving chemotherapy , to avoid over-treatment " .

西妥昔单抗是以表皮生长因子受体（EGFR）为作用靶点的嵌合性单抗，为目前常用的分子靶向治疗药物，疗效明确。

Cetuximab is a chimeric monoclonal antibody which targets to the epidermal growth factor receptor ( EGFR ) . As a commonly used drug , cetuximab has a clear effect .

非小细胞肺癌化疗及分子靶向治疗药物的研究进展

Development in chemotherapy and molecular targeted drugs of NSCLS

小分子靶向抗癌药物&蛋白酪氨酸激酶抑制剂研究进展

Research Advance of Small Molecular Targeted Anti-Tumor Agents TKIs

综合治疗在肺癌的冶疗中发挥着越来越重要的作用，其中的一个重大进展是分子靶向治疗药物的成叻应用。

Comprehensive therapy has been more and more important for the treatment of lung cancer .

肿瘤生物治疗的新热点&细胞、分子靶向性药物的发展

The highlight of current cancer biotherapy & development of cellular , molecular targeted new agents

然而，在临床中，仍有近三成的病人使用了目前国际上最先进的分子靶向治疗药物却没有效果。

However , in clinical practice , there are still Jinsan Cheng patients to use the current world 's most advanced molecular targeted therapies have no effect .

口服小分子靶向抗肿瘤药物的不良反应及防治措施

Prevention and treatments for adverse drug reactions of oral small molecular targeting drugs

丁健，中国医学科学院上海药物研究所，题目：分子靶向抗肿瘤药物研究进展。

Ding Jian , Shanghai Institute of Medicine of Chinese Academy of Medical Sciences , Topic : The Study Progress of molecular-targeted anti-tumor Drugs .